Table 1.
Positivity to total HPV DNA, HR-HPV, LR-HPV, Ct, total HPV plus Ct, HR-HPV plus Ct, and LR-HPV plus Ct in Brazilian women with cervical abnormalities (N = 252) without considering the multiple HPV infection
| Cervical cytology | HPV positivity n (%) | HPV plus Ct positivity n (%) | |||||
|---|---|---|---|---|---|---|---|
| HPV | HR-HPV | LR-HPV | HPV + Ct | HR-HPV + Ct | LR-HPV + Ct | Ct | |
| NILM (controls; N = 370) | 28 (7.60) | 14 (3.80) | 13 (3.51) | 4 (1.10) | 1 (0.27) | 3 (0.81) | 36 (9.73) |
| AGC (N = 6) | 2 (33.33) | 2 (33.33) | – | – | – | – | – |
| ASC-US (N = 93) | 37 (39.80)* | 19 (20.43) | 21 (22.60) | 8 (8.60) | 2 (2.15) | 6 (6.45) | 17 (18.30) |
| ASC-H (N = 38) | 26 (68.42)† | 21 (55.30)‡ | 5 (13.16) | 6 (15.80) | 5 (13.16) | 1 (2.63) | 7 (18.42) |
| LSIL (N = 55) | 42 (76.40)† | 30 (54.55)§ | 12 (21.82) | 8 (14.55) | 6 (10.91) | 3 (5.45) | 9 (16.40) |
| HSIL (N = 42) | 42 (100.0)† | 36 (85.71)† | 11 (26.20) | 7 (16.70) | 7 (16.70) | 1 (2.40) | 7 (16.70) |
| CC (N = 18) | 18 (100.0)† | 18 (100.0)† | 6 (33.33) | 3 (16.70) | 3 (16.70) | 2 (11.11) | 3 (16.70) |
| Total (N = 622) | 195 (31.35) | 140 (22.51) | 68 (10.93) | 36 (5.80) | 24 (3.86) | 16 (2.60) | 79 (12.70) |
P value < 0.05 is considered significant. Cytology findings: controls (NILM; N = 370); cases: AGCs (N = 6), ASC-US (N = 93), ASC-H (N = 38), LSIL (N = 55), HSIL (N = 42), and CC (N = 18).
*
P = 0.0053; P value compared HPV infection with ASC-US.
†
P = 0.0001; P value compared HPV infection with ASC-H, LSIL, HSIL, and CC and compared HR-HPV with HSIL and CC.
‡
P = 0.0037; P value compared HR-HPV infection with ASC-H.
§
P= 0.0025; P value compared HR-HPV infection with LSIL.